Signature Cord Prime™
Knee Osteoarthritis
Key Facts
About Arugula Sciences
Arugula Sciences is a private, clinical-stage biotech leveraging the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and acellular products. The company's lead program, Signature Cord Prime™, is in an FDA Phase 1 trial for knee osteoarthritis, with another Phase 1 study approved for big toe osteoarthritis. Founded in 2018, Arugula is pre-revenue and is building a platform around perinatal tissue biologics to treat a range of degenerative conditions, positioning itself in the competitive but high-growth cell and gene therapy sector.
View full company profileAbout Arugula Sciences
Arugula Sciences is a private, clinical-stage biotech leveraging the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and acellular products. The company's lead program, Signature Cord Prime™, is in an FDA Phase 1 trial for knee osteoarthritis, with another Phase 1 study approved for big toe osteoarthritis. Founded in 2018, Arugula is pre-revenue and is building a platform around perinatal tissue biologics to treat a range of degenerative conditions, positioning itself in the competitive but high-growth cell and gene therapy sector.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Progenza | Cambium Bio | Phase 1/2a |
| MAG200 | Magellan | Phase 3 |
| MUTI™ Knee Replacement | Meril | Commercial |
| DUROLANE | Bioventus | Commercial |
| XSTEM | Xintela | Phase I/IIa |
| Stempeucel® | Stempeutics Research | Commercial |
| Lipogems System for Knee Osteoarthritis | Lipogems International | Phase 3 |
| Knee Osteoarthritis Study | Arizona Research Center | Not Specified |
| 4P004 | 4Moving Biotech | Phase 2a |
| Lorecivivint (inferred) | Biosplice Therapeutics | Phase 3 |
| Regenerative Cell Therapy for Osteoarthritis | InGeneron | Phase 3 |
| ArthroCart | Arthro Biotech | Preclinical |